January 16th 2023
Sara Tolaney, MD, MPH, and Massimo Cristofanilli, MD, discuss factors that affect risk stratification of patients with HR+, HER2- breast cancer.
November 17th 2022
Dr Sara M Tolaney reviews data from the APHINITY trial regarding the pertuzumab plus trastuzumab and chemotherapy treatment regimen for patients with HER2+ breast cancer.
November 1st 2022
Breast medical oncologists close out the program on HR+ metastatic breast cancer by highlighting ongoing clinical trials with antibody-drug conjugate therapy.
October 25th 2022
Centering discussion on antibody-drug conjugates in HR+ metastatic breast cancer, panelists consider the selection and use of these agents in practice.
Centering their discussion on the HER2 low setting of HR+ metastatic breast cancer, medical oncologists review data behind trastuzumab deruxtecan therapy.
October 18th 2022
Shared insight on appropriate treatment options for patients with HR+ metastatic breast cancer following progression on CDK4/6 inhibitors.
Expert panelists consider when it is appropriate to continue the use of CDK4/6 inhibitors beyond progression in HR+ metastatic breast cancer.
October 11th 2022
In the context of recent clinical trials, experts share their perspective on the selection and use of CKD4/6 inhibitor therapy in patients with HR+ metastatic breast cancer.
Closing out their review of endocrine therapy in HR+ metastatic breast cancer, panelists consider clinical trial data with selective estrogen receptor modulators [SERMs].
October 4th 2022
Comprehensive insight to the development and use of selective estrogen receptor degraders [SERDs] in HR+ metastatic breast cancer treatment.
Opening their discussion on the HR+ metastatic breast cancer treatment landscape, expert oncologists share a broad overview of treatment modalities in this setting.
June 29th 2022
Before closing out the discussion on the management of HER2+ breast cancer, experts share their excitement on future treatment strategies.
June 22nd 2022
Experts consider how best to manage adverse events associated with the HER2CLIMB regimen in the setting of HER2+ metastatic breast cancer.
A brief discussion on optimally managing adverse events while treating patients with HER2+ breast cancer.
June 15th 2022
Sara Tolaney, MD, provides practical advice for managing interstitial lung disease in patients with metastatic HER2+ breast cancer.
Shared insight on factors for selecting therapy in a patient with HER2+ metastatic breast cancer progressing through multiple lines of therapy.
June 8th 2022
Expert oncologist Rena Callahan, MD, shares a real-world clinical scenario of a 43-year-old woman with metastatic breast cancer who progressed through multiple lines of therapy.
Expert perspectives on use of trastuzumab deruxtecan in patients with HER2+ breast cancer who develop brain metastases.
June 1st 2022
Centering discussion on a real-world patient profile, subject matter experts discuss use of the HER2CLIMB regimen in HER2+ breast cancer.
Considerations for the role of trastuzumab emtansine in HER2+ breast cancer with the advent of newer HER2-targeted therapies.